121 results on '"Papa, Sophie"'
Search Results
2. Acute kidney injury in patients treated with immune checkpoint inhibitors
3. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products
4. Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
5. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
6. Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
7. Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study
8. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience
9. Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
10. 18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
11. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
12. The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre
13. Understanding the Lived Experience of Patients with Melanoma: Real-World Evidence Generated through a European Social Media Listening Analysis (Preprint)
14. 458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
15. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
16. Development and Validation of a Good Manufacturing Process for IL-4-Driven Expansion of Chimeric Cytokine Receptor-Expressing CAR T-Cells
17. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
18. Abstract LB076: Association between regional COVID-19 hospitalizations and treatment delays amongst confirmed cancer patients in England, UK
19. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
20. COVID-19 Risk Factors for Cancer Patients: A First Report with Comparator Data from COVID-19 Negative Cancer Patients
21. 108 INFLIXIMAB TREATMENT FOR CHECKPOINT INHIBITOR INDUCED COLITIS: CLINICAL OUTCOMES FROM A MULTI-CENTRE STUDY
22. Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis.
23. Abstract P28: COVID-19 infection and mortality in patients with skin malignancies receiving systemic anti-cancer therapy (SACT): The Guy’s Cancer Centre experience
24. Utilizing Immunocytokines for Cancer Therapy
25. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients
26. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
27. Impact of age on the toxicity of immune checkpoint inhibition
28. Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
29. Factors Affecting COVID-19 Outcomes in Cancer Patients: A First Report From Guy's Cancer Center in London
30. Anosmia and ageusia are emerging as symptoms in patients with COVID-19: What does the current evidence say?
31. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
32. Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
33. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease
34. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
35. Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.
36. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
37. New Developments in Imaging Cell-Based Therapy
38. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis
39. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
40. BRAF inhibitors:resistance and the promise of combination treatments for melanoma
41. One Piece of the Jigsaw for the Cancer Recovery Strategy: Prevalence of COVID-19 in Patients With Cancer.
42. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells
43. BRAF inhibitors: resistance and the promise of combination treatments for melanoma
44. Abstract CT118: T4 immunotherapy of head and neck squamous cell carcinoma using pan-ErbB targeted CAR T-cells
45. Engineering T cell metabolism for enhanced CAR T cell efficacy
46. Engineering ErbB-targeted CAR T-cells to improve efficacy in treatment of solid tumours
47. Combination immunotherapy using ErbB re-targeted CAR T-cells and CRS inhibition
48. Optimising CAR T cell immunotherapy with a tumour microenvironment targeted immunocytokine
49. Chimeric antigen receptor (CAR) T-cell immunotherapy for MUC1-positive breast cancer
50. Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.